All biotechs at this stage of clinical trials with no product on market are valued on potential, but even then there's ways to to value them appropriately with future cash flows, years to market, and risk of trial failure, and we are falling way short of where we should be.
Argonaut say we should be 22 cents, but if you look at their past analysis it should really be 30 cents.
Those guys over at *** think we should be worth 50 cents.
Destiny Pharma is our closest competitor for BTX 1801, and they are valued at 150 million, and their stuff is not as good as ours.
What is a company worth today if it's almost guaranteed to bring in 500 million revenue in 2024/25 from BTX 1801 alone?
I'm all for the share price going down short term so I can buy more, don't get me wrong.
All biotechs at this stage of clinical trials with no product on...
-
- There are more pages in this discussion • 11,156 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $617.9M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 34.3¢ | 32.5¢ | $1.814M | 5.424M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 489055 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 340303 | 4 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |